Session » (2195–2226) Reproductive Issues in Rheumatic Disorders Posters

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2204

A Novel Framework for Teratogenicity Counseling for Adolescents and Young Adults (AYAs) with Rheumatic Disease on Teratogenic Medications

10:30AM-12:30PM: Abstract Number: 2201

Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys

10:30AM-12:30PM: Abstract Number: 2206

Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes

10:30AM-12:30PM: Abstract Number: 2213

Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 2210

Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2208

Contraception and Pregnancy Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2199

Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting

10:30AM-12:30PM: Abstract Number: 2205

Effectiveness of Reproductive Health Counseling for Rheumatology Patients

10:30AM-12:30PM: Abstract Number: 2195

Enhancing MTX and LEF Safety for Immunosuppressed Women of Childbearing Age with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 2202

Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees

10:30AM-12:30PM: Abstract Number: 2216

Expanding Reproductive Health Assessments in Rheumatic Diseases: A Comparative Analysis of Demographic and Disease-Specific Factors

10:30AM-12:30PM: Abstract Number: 2226

Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications

10:30AM-12:30PM: Abstract Number: 2224

Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE

10:30AM-12:30PM: Abstract Number: 2220

Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 2214

Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study

10:30AM-12:30PM: Abstract Number: 2212

Impact of the 2020 ACR Reproductive Health Guidelines on Treatment Strategies and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Single-Center Retrospective Study

10:30AM-12:30PM: Abstract Number: 2223

Improving collaboration between rheumatology and OBGYN in the reproductive health care of patients with rheumatic disease

10:30AM-12:30PM: Abstract Number: 2217

Improving Patient Counseling on Medication Safety During Reproductive Years

10:30AM-12:30PM: Abstract Number: 2211

Maternal Adverse Pregnancy Outcomes and Risk Factors in Patients with Systemic Lupus Erythematosus in the United States

10:30AM-12:30PM: Abstract Number: 2203

Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine

10:30AM-12:30PM: Abstract Number: 2197

Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation

10:30AM-12:30PM: Abstract Number: 2207

Menopause Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2222

Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort

10:30AM-12:30PM: Abstract Number: 2200

Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study

10:30AM-12:30PM: Abstract Number: 2215

Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes

10:30AM-12:30PM: Abstract Number: 2218

Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study

10:30AM-12:30PM: Abstract Number: 2209

Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS

10:30AM-12:30PM: Abstract Number: 2221

Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2196

Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series

10:30AM-12:30PM: Abstract Number: 2198

Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach

10:30AM-12:30PM: Abstract Number: 2225

The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers

10:30AM-12:30PM: Abstract Number: 2219

Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].